Safe to Stop MS Disease-Modifying Therapy After Age 60?

Share this post

To add more evidence to the controversial debate over stopping immunomodulatory therapy for multiple sclerosis after age 60, researchers focus on quality of life, walking performance, and relapse rates.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply